Stock Analysis on Net

IQVIA Holdings Inc. (NYSE:IQV)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 1, 2023.

Return on Capital (ROC)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Return on Invested Capital (ROIC)

IQVIA Holdings Inc., ROIC calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Net operating profit after taxes (NOPAT)1
Invested capital2
Performance Ratio
ROIC3
Benchmarks
ROIC, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 NOPAT. See details »

2 Invested capital. See details »

3 2022 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The analysis of the financial data reveals notable trends over the five-year period ended December 31, 2022.

Net Operating Profit After Taxes (NOPAT)
The NOPAT showed a steady increase from 2018 through 2020, rising from $444 million to $718 million. A significant jump occurred in 2021, where NOPAT more than doubled to $1,678 million. However, in 2022, there was a decrease to $1,268 million, representing a decline from the previous year but still substantially higher than the figures reported prior to 2021.
Invested Capital
The invested capital exhibited relatively stable growth throughout the period, increasing gradually from $20,458 million in 2018 to $21,926 million in 2022. The increments were modest and consistent year-over-year, suggesting a controlled increase in the capital base over time without sharp fluctuations.
Return on Invested Capital (ROIC)
The ROIC mirrored the trend observed in NOPAT, beginning at 2.17% in 2018 and remaining fairly flat through 2019. The rate increased to 3.4% in 2020, followed by a substantial rise to 7.9% in 2021, indicating improved efficiency and profitability relative to invested capital during that year. In 2022, the ROIC decreased to 5.78%, yet remained significantly higher than the initial years, signaling sustained enhanced returns despite the dip.

Overall, the data indicates that while the invested capital grew modestly, profitability and efficiency metrics saw marked improvement, particularly in 2021, before experiencing a partial retreat in 2022. This pattern suggests that the company achieved better operational performance and capital utilization starting in 2020, peaking in 2021, with some correction in the subsequent year.


Decomposition of ROIC

IQVIA Holdings Inc., decomposition of ROIC

Microsoft Excel
ROIC = OPM1 × TO2 × 1 – CTR3
Dec 31, 2022 = × ×
Dec 31, 2021 = × ×
Dec 31, 2020 = × ×
Dec 31, 2019 = × ×
Dec 31, 2018 = × ×

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Operating profit margin (OPM). See calculations »

2 Turnover of capital (TO). See calculations »

3 Effective cash tax rate (CTR). See calculations »


Operating Profit Margin (OPM)
The operating profit margin displayed a fluctuating trend over the analyzed period. Starting at 7.51% in 2018, it slightly declined to 7.26% in 2019, before experiencing a notable increase to 9.07% in 2020. The margin peaked at 14.31% in 2021, indicating a significant improvement in operational efficiency or profitability during that year, before decreasing to 12.08% in 2022, suggesting some reduction in margin but remaining at a relatively strong level compared to earlier years.
Turnover of Capital (TO)
Turnover of capital showed a gradual upward movement from 0.51 in 2018 to 0.55 in 2019 and remained steady at 0.55 in 2020. It then increased more notably to 0.68 in 2021, reflecting enhanced asset utilization or revenue generation from capital employed. In 2022, it slightly decreased to 0.66 but stayed higher than the initial years, indicating sustained relatively efficient capital use.
1 – Effective Cash Tax Rate (CTR)
The complement of the effective cash tax rate revealed a rising trend from 56.62% in 2018 to 81.15% in 2021, implying an increasing portion of earnings retained after tax payments over this period. However, this ratio decreased in 2022 to 72.99%, suggesting a higher tax burden or reduced tax efficiency compared to the prior year but still at a level above the years before 2020.
Return on Invested Capital (ROIC)
Return on invested capital showed significant improvement, beginning at a low 2.17% in 2018, maintaining a similar level in 2019 at 2.21%, and increasing to 3.4% in 2020. The ROIC nearly doubled to 7.9% in 2021, indicating much greater profitability and effectiveness in generating returns from capital invested. In 2022, ROIC declined to 5.78%, signaling a reduction in investment returns but remaining substantially above early-period levels.

Operating Profit Margin (OPM)

IQVIA Holdings Inc., OPM calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Net operating profit after taxes (NOPAT)1
Add: Cash operating taxes2
Net operating profit before taxes (NOPBT)
 
Revenues
Add: Increase (decrease) in unearned income
Adjusted revenues
Profitability Ratio
OPM3
Benchmarks
OPM, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 NOPAT. See details »

2 Cash operating taxes. See details »

3 2022 Calculation
OPM = 100 × NOPBT ÷ Adjusted revenues
= 100 × ÷ =

4 Click competitor name to see calculations.


Net Operating Profit Before Taxes (NOPBT)
The net operating profit before taxes exhibited a steady increase from 2018 through 2021, rising from 784 million USD to a peak of 2,067 million USD. However, in 2022, there was a noticeable decline to 1,737 million USD. This indicates strong growth over the initial four years followed by a reduction in profitability in the most recent period.
Adjusted Revenues
Revenues demonstrated a consistent upward trend from 2018 to 2021, increasing from 10,434 million USD to 14,447 million USD. In 2022, revenues slightly decreased to 14,382 million USD, showing relative stability but suggesting a plateau after years of growth.
Operating Profit Margin (OPM)
The operating profit margin followed an upward trajectory from 2018 (7.51%) to 2021 (14.31%), indicating improving operating efficiency and profitability. In 2022, the margin decreased to 12.08%, reflecting a reduction in operational profitability despite steady revenues.
Overall Analysis
The financial data reveals a general pattern of growth in both revenues and profitability from 2018 through 2021. The peak in net operating profit before taxes and operating profit margin in 2021 suggests the company's operations were most efficient and profitable during that year. The slight decline in both profit and margin in 2022, coupled with almost flat revenue, indicates potential challenges in maintaining prior growth momentum or increased costs impacting profitability. This pattern may warrant further investigation into cost structures, market conditions, or other external factors influencing the 2022 performance.

Turnover of Capital (TO)

IQVIA Holdings Inc., TO calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Revenues
Add: Increase (decrease) in unearned income
Adjusted revenues
 
Invested capital1
Efficiency Ratio
TO2
Benchmarks
TO, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Invested capital. See details »

2 2022 Calculation
TO = Adjusted revenues ÷ Invested capital
= ÷ =

3 Click competitor name to see calculations.


The financial data presented indicate distinct trends over a five-year period from 2018 to 2022. Adjusted revenues show a steady increase from US$10,434 million in 2018 to US$14,447 million in 2021, followed by a slight decline to US$14,382 million in 2022. This pattern suggests overall growth in revenues with a marginal reduction in the final year observed.

Invested capital exhibits a gradual upward trend, rising from US$20,458 million in 2018 to US$21,926 million in 2022. The growth in invested capital is relatively moderate compared to the changes in revenue, indicating cautious or controlled investment expansion over the period.

The turnover of capital ratio (TO), which measures the efficiency of using invested capital to generate revenue, increases from 0.51 in 2018 to a peak of 0.68 in 2021, before slightly decreasing to 0.66 in 2022. This improvement up to 2021 reflects enhanced operational efficiency or better utilization of capital in generating revenues. The slight decline in 2022 aligns with the marginal decrease in adjusted revenues during the same year.

Adjusted Revenues
Consistent growth over the initial four years, increasing by approximately 38% from 2018 to 2021, followed by a minor reduction in 2022.
Invested Capital
Incremental increases over the five years, demonstrating steady but limited capital investment growth.
Turnover of Capital (TO)
Improvement in capital efficiency till 2021, indicated by a rising ratio, with a slight decline in the final year suggesting a temporary reduction in capital usage efficiency.

Overall, the data reveal a trend of expanding revenues supported by modest increases in invested capital and improving capital turnover efficiency until 2021, with a slight reversal of these positive trends in 2022.


Effective Cash Tax Rate (CTR)

IQVIA Holdings Inc., CTR calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Net operating profit after taxes (NOPAT)1
Add: Cash operating taxes2
Net operating profit before taxes (NOPBT)
Tax Rate
CTR3
Benchmarks
CTR, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 NOPAT. See details »

2 Cash operating taxes. See details »

3 2022 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × ÷ =

4 Click competitor name to see calculations.


The financial data presents several notable trends over the five-year period from 2018 to 2022.

Cash Operating Taxes
The cash operating taxes exhibit a general upward trajectory, increasing from 340 million USD in 2018 to 469 million USD in 2022. This indicates a rising tax outflow despite some fluctuations, with a slight decline observed in 2020 followed by steady increases thereafter, reaching the highest level in 2022.
Net Operating Profit Before Taxes (NOPBT)
The net operating profit before taxes shows a significant increase over the period, from 784 million USD in 2018 to a peak of 2,067 million USD in 2021, representing more than a twofold rise. However, in 2022, this figure declined to 1,737 million USD. This pattern suggests strong profit growth initially, with some contraction in the most recent year.
Effective Cash Tax Rate (CTR)
The effective cash tax rate fluctuates notably during the period, starting at 43.38% in 2018 and peaking slightly higher at 44.2% in 2019. Thereafter, it declines sharply to a low of 18.85% in 2021 before rising again to 27.01% in 2022. This variability suggests changes in tax planning, profitability mix, or tax legislation impacting the overall tax burden.

Overall, operating profitability improved considerably through 2021, which led to higher absolute cash operating taxes in most years, despite a notable decrease in the effective tax rate during 2020 and 2021. The decline in profitability in 2022 partially explains the reduction in cash operating taxes that year, alongside the increase in the effective tax rate, signaling a complex interplay between earnings and taxation effects on the company’s tax expense profile.